This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Medical Practice  • Medical Ethics  • Neurology  • Alzheimer Disease  • Cognitive Disorders  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The Editorial by Drs DeAngelis and Fontanarosa¹ addressed publication policies and scientific ethics. We agree with many of the concerns expressed and with many of the proposed solutions. We have serious disagreement, however, about the recommendation to hold authors from for-profit companies and academic or government authors to different professional standards. Drs DeAngelis and Fontanarosa have previously argued that industry could submit biased reports favoring their products.² The argument that, because someone in a specified group could take a certain action, everyone in the group is suspect is unfair. The implied assumption that academic investigators are immune to outside influences is also unwarranted.

Our major concern is with the proposal that "[a]ll journals must require a statistical analysis of clinical trial data conducted by a statistician who is not an employee of a for-profit company." The involvement of a professional statistician in clinical research typically includes helping . . . [Full Text of this Article]

Peter A. Lachenbruch, PhD
peter.lachenbruch@oregonstate.edu
Department of Public Health
Oregon State University
Corvallis

Ronald Wasserstein, PhD
ron@amstat.org
American Statistical Association
Alexandria, Virginia

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Conflicts of Interest and Independent Data Analysis in Industry-Funded Studies--Reply
and
JAMA. ;294():2576-2577.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():900-900.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():900-901.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():901-901.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():901-901.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
, , and
JAMA. ;300():901-902.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():902-902.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():902-903.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():903-903.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():903-904.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
and
JAMA. ;300():904-904.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
, , and
JAMA. ;300():904-905.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
and
JAMA. ;300():905-906.
FULL TEXT  

RELATED ARTICLE

Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence
and
JAMA. ;299():1833-1835.
FULL TEXT